ATE453406T1 - Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) - Google Patents

Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)

Info

Publication number
ATE453406T1
ATE453406T1 AT97913955T AT97913955T ATE453406T1 AT E453406 T1 ATE453406 T1 AT E453406T1 AT 97913955 T AT97913955 T AT 97913955T AT 97913955 T AT97913955 T AT 97913955T AT E453406 T1 ATE453406 T1 AT E453406T1
Authority
AT
Austria
Prior art keywords
antibodies
identification
binding interactions
binding
certain antibodies
Prior art date
Application number
AT97913955T
Other languages
English (en)
Inventor
Darrell Anderson
Nabil Hanna
Peter Brams
Cheryl Heard
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE453406T1 publication Critical patent/ATE453406T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
AT97913955T 1996-11-08 1997-10-29 Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) ATE453406T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74636196A 1996-11-08 1996-11-08
PCT/US1997/019906 WO1998019706A1 (en) 1996-11-08 1997-10-29 Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens

Publications (1)

Publication Number Publication Date
ATE453406T1 true ATE453406T1 (de) 2010-01-15

Family

ID=25000516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97913955T ATE453406T1 (de) 1996-11-08 1997-10-29 Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)

Country Status (13)

Country Link
EP (2) EP1007090B1 (de)
JP (3) JP4048294B2 (de)
KR (1) KR100510604B1 (de)
CN (1) CN1198646C (de)
AT (1) ATE453406T1 (de)
AU (1) AU739058B2 (de)
BR (1) BR9713498A (de)
CA (1) CA2270922A1 (de)
DE (1) DE69739725D1 (de)
ID (1) ID21676A (de)
NO (1) NO992212L (de)
RU (1) RU2221590C2 (de)
WO (1) WO1998019706A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
CN1360596A (zh) 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
WO2001089567A1 (en) * 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2436180C (en) * 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
WO2003039486A2 (en) * 2001-11-09 2003-05-15 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
CA2574802A1 (en) * 2004-07-20 2006-02-02 Isogenis, Inc. Specific inhibition of autoimmunity and diseases associated with autoantigens
CN1817909B (zh) * 2005-02-08 2010-08-11 复旦大学 一种双功能融合蛋白
CN100369931C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人b7-1分子单克隆抗体及其应用
EP3530736A3 (de) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Humane monoklonale antikörper für den programmierten tod 1 (pd-1) und verfahren zur behandlung von krebs mit pd-1-antikörpern allein oder in kombination mit anderen immunotherapeutika
US7510844B2 (en) * 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2011127418A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
EP2804619B1 (de) * 2012-01-16 2021-10-13 Atox Bio Ltd. Reltecimod zur behandlung von bakteriellen infektionen
CZ306905B6 (cs) 2013-06-11 2017-09-06 Česká zemědělská univerzita v Praze Způsob pro stanovení vodní hodnoty sněhu sněhové vrstvy a zařízení pro provádění tohoto způsobu
CN106177931B (zh) * 2016-08-25 2018-02-02 河北浓孚雨生物科技有限公司 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法
EP3892299A4 (de) 2018-12-07 2022-11-30 ONO Pharmaceutical Co., Ltd. Immunsuppressionsmittel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091313A (en) * 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
DD297839A5 (de) * 1988-08-23 1992-01-23 Dana Farber Cancer Institute,Us Alpha-untereinheit des lfa-l-leukozytadhaesionsrezeptors
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies

Also Published As

Publication number Publication date
BR9713498A (pt) 2000-02-29
DE69739725D1 (de) 2010-02-11
CA2270922A1 (en) 1998-05-14
EP1007090A4 (de) 2001-03-14
NO992212D0 (no) 1999-05-06
JP2007330261A (ja) 2007-12-27
JP2001504693A (ja) 2001-04-10
RU2221590C2 (ru) 2004-01-20
WO1998019706A1 (en) 1998-05-14
JP4320381B2 (ja) 2009-08-26
NO992212L (no) 1999-07-08
AU5100998A (en) 1998-05-29
CN1244128A (zh) 2000-02-09
KR100510604B1 (ko) 2005-08-31
CN1198646C (zh) 2005-04-27
EP1878748A2 (de) 2008-01-16
HK1025741A1 (en) 2000-11-24
KR20000053137A (ko) 2000-08-25
EP1007090B1 (de) 2009-12-30
EP1007090A1 (de) 2000-06-14
JP4048294B2 (ja) 2008-02-20
JP2009001570A (ja) 2009-01-08
ID21676A (id) 1999-07-08
AU739058B2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
DE69739725D1 (de) Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)
Koulova et al. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells.
Pichler et al. T cells as antigen-presenting cells
ZA986084B (en) CTL epitopes from EBV
DK0892643T3 (da) Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
NL300220I1 (nl) Immunoglobuline varianten voor specifieke FC-epsilon receptoren.
NO963018L (no) CTLA4-mutantmolekyler og anvendelser derav
EP1194164B8 (de) Prion protein peptide und deren verwendung
GB9022011D0 (en) Chimaeric antibodies and their preparation
FR2695563B1 (fr) Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
ATE233814T1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
DE69736244D1 (de) Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
OA09384A (fr) "Système matriciel autoadhésif pour la libération prolongée du piribédil par voie transcutanée".
Ha et al. Aggressive skin allograft rejection in CD28−/− mice independent of the CD40/CD40L costimulatory pathway
Dasgupta et al. Involvement of major histocompatibility complex class I antigens in T cell activation
DE59008012D1 (de) Mittel zur Behandlung von Leder und Pelzen.
WO2003025000A3 (en) Peptides capable of modulating immune response
PL314414A1 (en) Antiidiotypic antibodies capable to induce an immunological response in respect to the receptor of epidermis growth factor
DE69221605D1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
Hämmerling et al. Cellular expression of Ia antigens and their possible role in immune reactions
Friccius et al. Induction of hyporesponsiveness in human lymphocytes-T despite their expression of both the co-receptor CD28 and its ligand B7
FR2718254B1 (fr) Lunettes, notamment de vue ou solaires, et monture s'y rapportant.
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties